10 THINGS YOU NEED TO KNOW ABOUT THE NIH
The National Institutes of Health supports remarkable scientific advances that improve and save lives, curb future healthcare spending, protect against international health threats, and help maintain global leadership.
- NIH is the largest public funder of biomedical research in the world.
- In fiscal year 2019, the NIH provided $30.82 billion in extramural research funding to scientists in all 50 states and the District of Columbia.
- In fiscal year 2019, NIH research funding directly and indirectly supported more than 475,000 jobs nationwide, and the income generated by these jobs, as well as by the purchase of research-related equipment, services and materials, produced more than $81 billion in new economic activity.
- Since 1969, the stroke mortality rate has decreased by 71%, due in part to NIH-funded research on treatments and prevention.
- The American Cancer Society estimates that 2.9 million lives were saved from 1991—2017 as a result of improvements in cancer treatment, detection, and prevention, many of which were funded and driven by NIH, resulting in a 29% drop in the cancer death rate over the last 30 years.
- Researchers funded by the NIH are rolling up their sleeves to develop and test vaccines and therapies for COVID-19 in an impressively short timeframe, joining forces with leading pharmaceutical companies to accelerate the pandemic response.
- NIH scientists have played a major role in working to address the national opioid crisis by working to develop safe, effective medicines for chronic pain, create a vaccine to protect against opioid misuse, and improve overdose prevention and reversal interventions.
- Since the mid-1990s, NIH research has driven HIV testing and preventive interventions, resulting in a more than 90% decrease in the number of U.S. children perinatally infected with HIV.
- NIH-supported researchers have made transformative advances in the use of gene therapy and gene editing over the last decade, creating promising and potentially curative treatment pathways for a growing number of conditions from sickle cell disease to cancer to HIV.
- YET . . . even with recent Congressional investments, NIH’s purchasing power is still below its 2003 level, and billions are needed to close the gap.